Wall Street analysts expect ASLAN PHARMACEU/ADR (NASDAQ:ASLN) to report earnings of ($0.20) per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for ASLAN PHARMACEU/ADR’s earnings, with the lowest EPS estimate coming in at ($0.21) and the highest estimate coming in at ($0.20). ASLAN PHARMACEU/ADR posted earnings per share of ($0.35) in the same quarter last year, which would indicate a positive year over year growth rate of 42.9%. The company is expected to announce its next quarterly earnings report on Monday, August 5th.
On average, analysts expect that ASLAN PHARMACEU/ADR will report full year earnings of ($0.73) per share for the current fiscal year, with EPS estimates ranging from ($0.75) to ($0.69). For the next financial year, analysts expect that the company will post earnings of ($0.83) per share, with EPS estimates ranging from ($1.11) to ($0.52). Zacks’ EPS calculations are an average based on a survey of research firms that follow ASLAN PHARMACEU/ADR.
ASLAN PHARMACEU/ADR (NASDAQ:ASLN) last released its earnings results on Friday, March 22nd. The company reported ($0.35) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.37) by $0.02.
ASLN opened at $3.55 on Friday. The company has a quick ratio of 5.19, a current ratio of 3.64 and a debt-to-equity ratio of 0.46. ASLAN PHARMACEU/ADR has a 1-year low of $2.51 and a 1-year high of $10.44.
An institutional investor recently bought a new position in ASLAN PHARMACEU/ADR stock. FNY Investment Advisers LLC purchased a new position in shares of ASLAN PHARMACEU/ADR (NASDAQ:ASLN) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 26,402 shares of the company’s stock, valued at approximately $104,000. FNY Investment Advisers LLC owned about 0.08% of ASLAN PHARMACEU/ADR at the end of the most recent reporting period. Hedge funds and other institutional investors own 9.34% of the company’s stock.
ASLAN PHARMACEU/ADR Company Profile
ASLAN Pharmaceuticals Limited, a clinical-stage oncology-focused biopharmaceutical company, engages in the development of drugs for prevalent cancers. It targets diseases that are prevalent in Asia, and orphan indications in the United States and Europe. The company's lead program, varlitinib, is a reversible small molecule pan-human epidermal growth factor receptor, or pan-HER, inhibitor that targets the human epidermal growth factor receptors HER1, HER2, and HER4.
Further Reading: What are the qualifications of a portfolio manager?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ASLAN PHARMACEU/ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ASLAN PHARMACEU/ADR and related companies with MarketBeat.com's FREE daily email newsletter.